Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Ampio Pharmaceuticals, Inc. (AMPE : OTC)
 
 • Company Description   
Ampio Pharmaceuticals, Inc. develops proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation, CNS disease, and male sexual dysfunction. Principal products offered by the Company include Optina, an oral drug for the treatment of diabetic retinopathy and macular edema; and Vasaloc, an oral drug for the treatment of diabetic nephropathy. Ampio Pharmaceuticals, Inc. is based in Greenwood Village, Colorado.

Number of Employees:

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.01 Daily Weekly Monthly
20 Day Moving Average: 1,580 shares
Shares Outstanding: 1.14 (millions)
Market Capitalization: $0.01 (millions)
Beta: 5.07
52 Week High: $0.16
52 Week Low: $0.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 92.59% 87.55%
12 Week 92.59% 84.61%
Year To Date 100.00% 74.82%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
9800 MOUNT PYRAMID COURT SUITE 400
-
ENGLEWOOD,CO 80112
USA		 ph: 720-437-6500
fax: 720-437-6501		 info@ampiopharma.com http://www.ampiopharma.com
 
 • General Corporate Information   
Officers
Michael A. Martino - Chief Executive Officer and Director
J. Kevin Buchi - Chairman
Daniel G. Stokely - Chief Financial Officer
David R. Stevens - Director
Elizabeth Varki Jobes - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 03209T307
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: -
Next Expected EPS Date: -
Share - Related Items
Shares Outstanding: 1.14
Most Recent Split Date: 9.00 (0.05:1)
Beta: 5.07
Market Capitalization: $0.01 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: -  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.00
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
09/30/25 - -
06/30/25 - -
03/31/25 - -
ROA
09/30/25 - -
06/30/25 - -
03/31/25 - -
Current Ratio
09/30/25 - -
06/30/25 - -
03/31/25 - -
Quick Ratio
09/30/25 - -
06/30/25 - -
03/31/25 - -
Operating Margin
09/30/25 - -
06/30/25 - -
03/31/25 - -
Net Margin
09/30/25 - -
06/30/25 - -
03/31/25 - -
Pre-Tax Margin
09/30/25 - -
06/30/25 - -
03/31/25 - -
Book Value
09/30/25 - -
06/30/25 - -
03/31/25 - -
Inventory Turnover
09/30/25 - -
06/30/25 - -
03/31/25 - -
Debt-to-Equity
09/30/25 - -
06/30/25 - -
03/31/25 - -
Debt-to-Capital
09/30/25 - -
06/30/25 - -
03/31/25 - -
 

Powered by Zacks Investment Research ©